Avanos eliminates CCO and GC roles; final severance includes full vesting of James's 16,300 RSUs

AVANOS MEDICAL, INC.

Company eliminated Chief Commercial Officer and General Counsel positions effective Dec 1, 2025 as part of restructuring.
Kerr Holbrook (CCO) and Mojirade James (GC) terminated; responsibilities reallocated.
Severance: Holbrook $1,535,417; James $1,425,665; plus COBRA, prorated bonuses, equity vesting.
16,300 time-based RSUs granted to James on April 22, 2025 vested fully on Dec 1, 2025.
Unvested awards treated as retirement; time-based PRSUs pro-rata vested, performance-based vest at end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.